AmCad BioMed Corporation (4188.TWO)
- Previous Close
14.75 - Open
14.60 - Bid 15.35 x --
- Ask 15.40 x --
- Day's Range
14.55 - 16.00 - 52 Week Range
12.30 - 31.00 - Volume
90,011 - Avg. Volume
54,546 - Market Cap (intraday)
975.327M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.84 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases, such as thyroid cancers, fatty liver, liver fibrosis, and obstructive sleep apnea. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-CA, a software device for analyzing digital cytological images; AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UV, a software device for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals. The company was incorporated in 2008 and is based in Taipei City, Taiwan.
www.amcad.com.twRecent News: 4188.TWO
View MorePerformance Overview: 4188.TWO
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4188.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4188.TWO
View MoreValuation Measures
Market Cap
975.33M
Enterprise Value
576.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.83
Price/Book (mrq)
1.78
Enterprise Value/Revenue
11.13
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-97.51%
Return on Assets (ttm)
-7.18%
Return on Equity (ttm)
-9.80%
Revenue (ttm)
51.81M
Net Income Avi to Common (ttm)
-50.52M
Diluted EPS (ttm)
-0.84
Balance Sheet and Cash Flow
Total Cash (mrq)
407.14M
Total Debt/Equity (mrq)
1.33%
Levered Free Cash Flow (ttm)
-34.96M